GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Buyback Yield %

KAPA (Kairos Pharma) Buyback Yield % : 0.00 (As of Apr. 17, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Kairos Pharma's current buyback yield was 0.00%.

Kairos Pharma Buyback Yield % Historical Data

The historical data trend for Kairos Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Buyback Yield % Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Buyback Yield %
- - - -

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kairos Pharma's Buyback Yield %

For the Biotechnology subindustry, Kairos Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's Buyback Yield % falls into.


;
;

Kairos Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Kairos Pharma's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 0
=N/A%

Kairos Pharma's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 20.16979
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Kairos Pharma Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kairos Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Buyback Yield %
Comparable Companies
NERV AAGH BRTX BIXT SNSE AFMD BCDA NYMXF SPRB LPTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064
Website
https://kairospharma.com
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.